In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price target of $120.00. The company’s shares opened today at $110.00.
O’Brien covers the Healthcare sector, focusing on stocks such as Dexcom, Boston Scientific, and Conmed. According to TipRanks, O’Brien has an average return of 5.8% and a 51.84% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TransMedics Group with a $111.17 average price target, a 1.06% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $130.00 price target.
The company has a one-year high of $99.63 and a one-year low of $36.42. Currently, TransMedics Group has an average volume of 783.6K.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransMedics Group (TMDX) Company Description:
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
Read More on TMDX:
